drugset / Trial / NCT04497688

Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma

NCT04497688

NaSingle-groupOpen-labelPrevention

Summary

The main treatments for non-Hodgkin's lymphoma are surgery, radiotherapy, chemotherapy, and bone marrow transplantation. Neutropenia is the most common and serious complication of most chemotherapy. This study is a multi-center, open-label, single-arm clinical study to evaluate the efficacy and safety of jinyouli in preventing neutropenia in patients with non Hodgkin's lymphoma after chemotherapy.

Timeline

Start
2019-01-01
Primary completion
2020-09-01
Completion
2020-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic 3 mg Subcutaneous
Subject Pegfilgrastim Protein / enzyme biologic 6 mg Subcutaneous

Indications